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The subclassification of medulloblastoma into its four consensus molecular 
subgroups is rapidly informing disease treatment and risk-stratification. DNA-
methylation microarrays have been essential for subgroup discovery and assignment 
in research studies, however their clinical utility is limited by expense, platform-
specificity, sample number/quality requirements and practicality. Here, we aimed to 
(i) develop a rapid and robust, low-cost, array-independent, subgrouping assay 
suitable for routine diagnostic sub-classification of single samples, and (ii) assess its 
application to scant, poor-quality and historical samples, including the previously 
unassignable HIT-SIOP-PNET4 trial cohort of standard-risk medulloblastomas.  
Using a cross-validated classification model, a minimal, multiply-redundant, 17-locus 
signature was derived to assign subgroup from 220 medulloblastomas profiled using 
Illumina 450K DNA-methylation arrays.  We next adapted Agena’s iPLEX assay to 
interrogate DNA methylation at these loci following bisulfite treatment. After in-vitro 
validation, the assay was applied to 101 independent DNA extracts from tumour 
material (fresh-frozen, FFPE and nuclear preparations (<30,000 nuclei)), representing 
all subgroups. Subgroup assignments from an optimised machine learning model 
were compared against gold-standard 450K calls for this validation cohort. 95/101 
samples passed QC thresholds (technical, subgroup assignment confidence); all 95 
recapitulated their corresponding 450K subgroup call. Assay turnaround (DNA 
extraction to result) was <5 days. 
Following validation, subgrouping was attempted in 153 HIT-SIOP-PNET4 samples, 
previously unclassifiable due to sample limitations (e.g. scant FFPE material, nuclear 
preparations, <50ng dsDNA (>250ng required, 450K/EPIC array)). High-confidence 
calls were made for 70% (107/153) of samples. MBGroup4 predominated (62/107) in 
this standard-risk cohort and subgroups showed predicted relationships to clinical, 
pathological and molecular demographics. 
In summary, single medulloblastoma samples can be routinely, rapidly and robustly 
subgrouped using low-cost minimal DNA-methylation signatures and technologies 
(Agena) transferrable to many diagnostics laboratories. Importantly, the assay is 
applicable to limited and low-quality samples refractory to array-based analysis, 
allowing the retrospective unlocking of subgroup status in historical trials cohorts. 
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